N※N

Lisbon Investigates Severe Mpox Case with Encephalitis

  //travel-leisure.news-articles.net/content/2026/ .. stigates-severe-mpox-case-with-encephalitis.html
  Published in Travel and Leisure on Monday, March 16th 2026 at 20:37 GMT by People
      Locales: UNITED STATES, UNITED KINGDOM

Lisbon, Portugal - March 17th, 2026 - Portuguese health officials are investigating a particularly severe case of mpox (formerly known as monkeypox) that has emerged in Lisbon, raising concerns about potential changes in the virus's behavior and the possibility of more serious complications than previously understood. The case, the first documented instance of such severity in Portugal, involves an adult male who has developed both encephalitis - inflammation of the brain - and extensive, severe skin lesions, necessitating admission to intensive care.

While mpox has been present globally since its initial resurgence in 2022, and vaccination campaigns have been largely successful in mitigating its spread, this new case deviates from the typical presentation. Early reports suggest the patient experienced a rapid progression of symptoms, escalating quickly from initial skin manifestations to neurological involvement. This atypical progression is what's driving the current investigation.

The patient, whose identity remains confidential to protect his privacy, was admitted to a Lisbon hospital last week after exhibiting a constellation of symptoms, including high fever, debilitating headache, and the characteristic mpox rash. However, the rash proved to be unusually widespread and aggressively progressing, quickly followed by the onset of neurological symptoms indicating potential encephalitis. Diagnostic tests confirmed the presence of the mpox virus, but also revealed evidence of significant inflammation within the brain tissue.

"This case is a wake-up call," stated Dr. Isabel Oliveira, Head of Infectious Diseases at Lisbon's Hospital Santa Maria. "While the majority of mpox infections remain mild to moderate, this patient's condition demonstrates the virus's potential to cause severe, life-threatening complications, even in individuals who have received vaccination. We need to understand what factors contributed to this severe outcome."

The Portuguese National Health Directorate (DGS) has launched a comprehensive investigation, focusing on several key areas. First, they are attempting to determine the specific strain of mpox involved. Genetic sequencing will be crucial to identify if the virus has mutated, potentially acquiring increased virulence or a different pathogenesis. Second, investigators are meticulously reviewing the patient's vaccination history and immune status to assess the effectiveness of the current vaccines against this particular strain. While current vaccines (JYNNEOS and ACAM2000) have demonstrated efficacy, the potential for 'breakthrough' infections with severe outcomes isn't entirely unexpected, and this case provides a critical opportunity to evaluate vaccine protection in the face of potential viral evolution.

Contact tracing efforts are also underway, aiming to identify and monitor all individuals who may have been exposed to the patient. This includes reviewing the patient's recent travel history and social contacts. The DGS is emphasizing the continued importance of preventative measures, including vaccination for eligible individuals, practicing good hygiene, avoiding close contact with symptomatic individuals, and safe sexual practices. The health authority is also stressing the importance of early detection and prompt medical attention for anyone exhibiting symptoms consistent with mpox.

Experts are debating several possible explanations for the severity of this case. One possibility is that the patient may have an underlying immunocompromising condition, making him more susceptible to severe complications. Another hypothesis is that the virus may have undergone a mutation, increasing its virulence. A third, and perhaps more likely scenario, is a combination of factors, including individual susceptibility, vaccine waning immunity, and potential viral evolution.

The World Health Organization (WHO) is monitoring the situation in Portugal closely. Dr. Maria Van Kerkhove, leading the WHO's emerging disease team, released a statement urging vigilance globally: "This case serves as a reminder that mpox remains a public health concern. It's crucial for countries to maintain surveillance systems, continue vaccination efforts, and be prepared to respond rapidly to any emerging clusters or severe cases."

The incident highlights a critical need for continued research into mpox, including studies on viral evolution, vaccine efficacy, and the development of novel therapeutic interventions. The Portuguese DGS plans to share its findings with the WHO and other international health organizations to inform global mpox control strategies and ensure a coordinated response to this evolving threat.